In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Assertio Therapeutics (ASRT – Research Report), with a price target of $3.50.
Ram Selvaraju’s rating is based on a combination of factors including Assertio Therapeutics’ recent financial performance and future prospects. Despite a modest top-line revenue beat in 2024, the company provided a lukewarm revenue guidance for 2025, which suggests a slower ramp-up in ROLVEDON sales and ongoing generic erosion of the INDOCIN franchise. However, Selvaraju remains optimistic about the company’s long-term potential, projecting a return to profitability by the second half of 2026 and estimating a total revenue of $135.6 million for that year.
Additionally, Selvaraju highlights the potential for improved gross margins as ROLVEDON becomes a larger part of Assertio’s sales mix. The company’s intent to introduce another branded commercial product in the U.S. market could also positively impact its financials. Using a discounted cash flow valuation approach, Selvaraju has set a price target of $3.50 per share, reflecting the company’s enterprise value and cash position, while acknowledging risks such as market competition and litigation challenges.
According to TipRanks, Selvaraju is a 4-star analyst with an average return of 4.9% and a 39.16% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Vanda, Axsome Therapeutics, and Emergent Biosolutions.
In another report released on March 14, Alliance Global Partners also maintained a Buy rating on the stock with a $1.75 price target.